Rafael G Amado

Summary

Affiliation: Amgen Inc
Country: USA

Publications

  1. doi request reprint Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
    Rafael G Amado
    Amgen, Inc, One Amgen Center Dr, MS 38 2 B, Thousand Oaks, CA 91320 1799, USA
    J Clin Oncol 26:1626-34. 2008
  2. doi request reprint Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone
    Daniel J Freeman
    Department of Oncology Research, Amgen Inc, Thousand Oaks, CA 91320, USA
    Clin Colorectal Cancer 7:184-90. 2008
  3. ncbi request reprint From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice
    Aya Jakobovits
    Agensys, Inc, 2225 Colorado Blvd, Santa Monica, California 90404, USA
    Nat Biotechnol 25:1134-43. 2007
  4. ncbi request reprint Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer
    Eric Van Cutsem
    Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium
    J Clin Oncol 25:1658-64. 2007
  5. ncbi request reprint Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer
    J Randolph Hecht
    University of California School of Medicine, Los Angeles, CA, USA
    Cancer 110:980-8. 2007
  6. ncbi request reprint Anti-human immunodeficiency virus hematopoietic progenitor cell-delivered ribozyme in a phase I study: myeloid and lymphoid reconstitution in human immunodeficiency virus type-1-infected patients
    Rafael G Amado
    Department of Medicine and UCLA AIDS Institute, University of California, Los Angeles, CA 90095, USA
    Hum Gene Ther 15:251-62. 2004
  7. ncbi request reprint Darbepoetin alfa for the treatment of chemotherapy-induced anemia: disease progression and survival analysis from four randomized, double-blind, placebo-controlled trials
    Michael Hedenus
    Department of Internal Medicine, Sundsvall Hospital, Sundsvall S 851 86, Sweden
    J Clin Oncol 23:6941-8. 2005
  8. ncbi request reprint Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer
    Jordan Berlin
    Vanderbilt University Medical Center, Nashville, TN 37232 6307, USA
    Clin Colorectal Cancer 6:427-32. 2007
  9. doi request reprint Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies
    Louis M Weiner
    Georgetown University Medical Center, Washington, DC 20057 1465, USA
    Clin Cancer Res 14:502-8. 2008

Detail Information

Publications9

  1. doi request reprint Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
    Rafael G Amado
    Amgen, Inc, One Amgen Center Dr, MS 38 2 B, Thousand Oaks, CA 91320 1799, USA
    J Clin Oncol 26:1626-34. 2008
    ..Although activating mutations in KRAS, a small G-protein downstream of EGFR, correlate with poor response to anti-EGFR antibodies in mCRC, their role as a selection marker has not been established in randomized trials...
  2. doi request reprint Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone
    Daniel J Freeman
    Department of Oncology Research, Amgen Inc, Thousand Oaks, CA 91320, USA
    Clin Colorectal Cancer 7:184-90. 2008
    ..Identifying predictive biomarkers is important to optimally treat patients. This analysis evaluated the association of K-ras, BRAF, and PIK3CA gene mutations with tumor resistance to panitumumab alone...
  3. ncbi request reprint From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice
    Aya Jakobovits
    Agensys, Inc, 2225 Colorado Blvd, Santa Monica, California 90404, USA
    Nat Biotechnol 25:1134-43. 2007
    ..The successful development of panitumumab represents a milestone for mice engineered with a human humoral immune system and their future applications...
  4. ncbi request reprint Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer
    Eric Van Cutsem
    Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium
    J Clin Oncol 25:1658-64. 2007
    ..We compared the activity of panitumumab plus best supportive care (BSC) to that of BSC alone in patients with metastatic colorectal cancer who had progressed after standard chemotherapy...
  5. ncbi request reprint Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer
    J Randolph Hecht
    University of California School of Medicine, Los Angeles, CA, USA
    Cancer 110:980-8. 2007
    ..The safety and efficacy of the fully human antibody panitumumab was evaluated in patients with metastatic colorectal cancer refractory to available therapies...
  6. ncbi request reprint Anti-human immunodeficiency virus hematopoietic progenitor cell-delivered ribozyme in a phase I study: myeloid and lymphoid reconstitution in human immunodeficiency virus type-1-infected patients
    Rafael G Amado
    Department of Medicine and UCLA AIDS Institute, University of California, Los Angeles, CA 90095, USA
    Hum Gene Ther 15:251-62. 2004
    ....
  7. ncbi request reprint Darbepoetin alfa for the treatment of chemotherapy-induced anemia: disease progression and survival analysis from four randomized, double-blind, placebo-controlled trials
    Michael Hedenus
    Department of Internal Medicine, Sundsvall Hospital, Sundsvall S 851 86, Sweden
    J Clin Oncol 23:6941-8. 2005
    ..To determine the effect of darbepoetin alfa (DA) on progression-free survival (PFS) and overall survival (OS) in patients with chemotherapy-induced anemia (CIA)...
  8. ncbi request reprint Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer
    Jordan Berlin
    Vanderbilt University Medical Center, Nashville, TN 37232 6307, USA
    Clin Colorectal Cancer 6:427-32. 2007
    ..We conducted this phase II study to assess the ability of panitumumab to be administered with first-line irinotecan-containing regimens in patients with mCRC...
  9. doi request reprint Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies
    Louis M Weiner
    Georgetown University Medical Center, Washington, DC 20057 1465, USA
    Clin Cancer Res 14:502-8. 2008
    ....